Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration …………… Goel V, Gosselin NH, Jomphe C, Zhang X, Marier JF, Robbie GJ. Nucleic Acid Ther. 2020 Mar 12. PubMed 00
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis …………… Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH 3rd, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT,…
MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial …………… Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DR, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra…
Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles …………… Chen CY, Tran DM, Cavedon A, Cai X, Rajendran R, Lyle MJ, Martini PGV, Miao CH. Mol Ther Nucleic Acids. 2020 Apr 7;20:534-544 PubMed 00